Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome

Kevin Bryan Lo; Karim Iskarous; Rajiv Sankaranarayanan

doi:10.1016/j.ccl.2024.12.002

Back

Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome

Article 2025 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias

Vikash Jaiswal, Song Peng Ang, Danisha Kumar, Novonil Deb, Akash Jaiswal, Amey Joshi, Yusra Nasir, Dhrubajyoti Bandyopadhyay, Erin D. Michos, Emelia Benjamin, Gregg C. Fonarow

Letter2024

Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes

Steven Ho Man Lam, Uazman Alam, Professor Gregory Lip

Article2022

Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?

Riccardo Proietti, Professor Gregory Lip

Preprint2024

Outcomes associated with Sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients: A real-world analysis using a global federated database.

Elin Davies, Nageen Anwar, Philip Austin, Christopher Wong, Mark A.J. Devonald, Professor Gregory Lip, Oni Louise, Garry McDowell, Anirudh Rao

Article2023

Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database

Nageen Anwar, Elin Haf Davies, Mark A.J. Devonald, Professor Gregory Lip, Garry McDowell, Anirudh Rao